Aligos Therapeutics, Inc. (ALGS) AI Stock Analysis

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in viral and liver diseases. Headquartered in South San Francisco, California, the company was established in 2018. Its lead drug candidate is ALG-010133, an oligonucleotide polymer in Phase Ib clinical trials for chronic hepatitis B. Its pipeline also includes ALG-000184, ALG-020572, and ALG-055009, a small molecule THR-β agonist in Phase 1a/1b for non-alcoholic steatohepatitis. Aligos maintains strategic research collaborations with Luxna Biotech Co., Ltd., Emory University, Katholieke Universiteit Leuven, and Merck.

Annual revenue at Aligos Therapeutics fluctuated from $4.4M in FY2021 to $13.9M in FY2022 and $15.5M in FY2023, before falling 74.6% to $3.9M in FY2024. In FY2025, revenue dropped 44.6% to $2.2M, alongside a gross margin of 57.5% and an operating margin of -4024.9%. Net income stood at -$24.2M in FY2025, an improvement from -$131.2M in FY2024, resulting in an EPS of -$1.36. Research and development expenses were $69.5M in FY2025. For the trailing twelve months ending June 30, 2026, revenue totaled $31.5M, supported by quarterly revenue growth of 2778.5% year-over-year in the latest quarter.

As of June 30, 2026, Aligos Therapeutics held $30.4M in cash and short-term investments against $3.5M in total debt, leaving net cash of $26.9M. Total assets stood at $66.3M, supporting shareholders' equity of $31.9M. The company maintains a current ratio of 2.19 and a debt-to-equity ratio of 0.11. Operating cash flow in FY2025 was -$82.5M, and free cash flow was -$82.9M after capital expenditures of $437,000.

Aligos Therapeutics trades at a market capitalization of $30.3M and an enterprise value of $7.8M. Its price-to-sales ratio is 1.0x, below the 4.1x median of its US-listed Healthcare peers. The company has a price-to-book ratio of 1.1x and an EV-to-EBITDA ratio of 0.6x compared to the peer median of 12.0x. Over the past year, the stock fell 53.8%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock's return of -98.8% trailed the 83.0% return of the benchmark index.

Wall Street coverage on Aligos Therapeutics consists of 7 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $52.38, representing an upside of 977.7% over the last close of $4.86 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts forecast revenue of $36.0M and an EPS of -$6.52. Aligos beat EPS expectations in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Aligos Therapeutics, Inc. (ALGS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALGS income statement, ALGS balance sheet, ALGS key metrics, ALGS analyst forecast, ALGS chart. See the ALGS stock overview for the latest quote and news.